๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Clinical value of SDI test for predicting effect of postoperative chemotherapy for patients with gastric cancer

โœ Scribed by Hideo Baba; Hideya Takeuchi; Sadaaki Inutsuka; Manabu Yamamoto; Kazuya Endo; Shinji Ohno; Yoshihiko Maehara; Keizo Sugimachi


Publisher
John Wiley and Sons
Year
1994
Tongue
English
Weight
390 KB
Volume
10
Category
Article
ISSN
8756-0437

No coin nor oath required. For personal study only.

โœฆ Synopsis


We retrospectively evaluated the clinical usefulness of the succinate dehydrogenase inhibition (SDI) test as a chemosensitivity test, using 168 resected specimens of gastric cancer, with special reference to the correlation between the results of the SDI test and clinical effects of the corresponding chemotherapy. The rate of sensitivity of these tissues to DDP, CQ, ACR, MMC, ADM, and 5-FU were 63.59'0, 54.29'0, 47.4%, 42.9%,, 3 1.4%, and 10.8%, respectively. Survival rates for patients with a positive chemosensitivity to MMC and postoperatively prescribed more than 20 mg of MMC were significantly better than those without sensitivity to MMC, even when treated with MMC, although no statistical differences existed in clinicopathologic factors between the two groups. We conclude that the SDI test for human gastric cancer is a rapid, reliable. and useful assay to determine the compatibility between the results of assay and the clinical effects of corresponding chemotherapy. We propose that the regimen of postoperative adjuvant chemotherapy be tailored according to results of the SDI test, using tissues resected from individual patients. Q 1994 WiIey-Liss. Inc.


๐Ÿ“œ SIMILAR VOLUMES


Dose intensity of mitomycin C in adjuvan
โœ Tetsuro Kubota; Koichiro Kumai; Masaki Kitajima; Osahiko Abe; Masato Fujisaki; Y ๐Ÿ“‚ Article ๐Ÿ“… 1994 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 521 KB

Using a cohort of macroscopic curative resections of gastric cancer at stages 11, Ill, and IV, a randomized controlled trial was performed to clucidate the dose efficacy of intensive adjuvant cancer chemotherapy with mitomycin C. Between June 1983 and December 1986, 336 patients with gastric cancer